Skip to main content
OpenTrials

Clinical trial condition

Mast Cell Activation Disorders

Explore clinical trials studying Mast Cell Activation Disorders. Study availability and eligibility vary by location and protocol.

96 public trials 17 recruiting studies
Refine in advanced search Browse all conditions

Mast Cell Activation Disorders trial results

Active, not recruiting

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

NCT03779854

Conditions
Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, +54 more
Locations
  • Children's Hospital of Los Angeles Los Angeles, California, United States
  • Children's Healthcare of Atlanta Atlanta, Georgia, United States
  • University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa, United States
  • Dana Farber / Boston Children's Hospital Boston, Massachusetts, United States
View Trial Details
Active, not recruiting

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

NCT05362773

Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm, Bone Marrow Diseases, Chronic Disease, +37 more
Locations
  • Colorado Blood Cancer Network Denver, Colorado, United States
  • University of Maryland, Greenbaum Comprehensive Cancer Center Baltimore, Maryland, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • START - Midwest Grand Rapids, Michigan, United States
View Trial Details
Active, not recruiting

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

NCT05186753

Conditions
BMM, Bone Marrow Mastocytosis, Hematologic Diseases, +15 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Mayo Clinic Arizona Phoenix, Arizona, United States
  • One of a Kind Clinical Research Center Scottsdale, Arizona, United States
  • Modena Allergy and Asthma Clinical La Jolla, California, United States
View all 57 locations
View Trial Details
Active, not recruiting

(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

NCT03731260

Conditions
Immune System Diseases, Indolent Systemic Mastocytosis, Mast Cell Activation Disorders, +6 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Mayo Clinic Hospital Phoenix, Arizona, United States
  • Stanford Cancer Institute Stanford, California, United States
  • Mayo Clinic Florida Jacksonville, Florida, United States
View all 49 locations
View Trial Details
Completed

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

NCT03580655

Conditions
Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Hematologic Diseases, +15 more
Locations
  • Stanford Cancer Institute Stanford, California, United States
  • Rush University Medical Center Chicago, Illinois, United States
  • The University of Kansas Cancer Center Westwood, Kansas, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View all 32 locations
View Trial Details

Related conditions